Related Experiment Video
Updated: Jan 4, 2026
Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
Published on: May 31, 2024
Efficacy of adalimumab therapy in experimental rat sclerosing encapsulated peritonitis model
Yeliz Akgun, Serkan Bakirdogen1, Meral Gulay Kadioglu Kocak
1Serkan Bakirdogen, Division of Nephrology, Department of Internal Medicine, Canakkale Onsekiz Mart University, School of Medicine, Canakkale, Turkey, sbdogen@comu.edu.tr.
Aim:
To investigate the efficacy of adalimumab treatment in an experimental rat sclerosing encapsulated peritonitis (SEP) model.
Methods:
The study involved 40 Wistar albino rats divided into four groups: chlorhexidine (CH) group, control group, CH + adalimumab group, and CH + resting group. The control group received normal saline intraperitoneally (i.p.). Other groups received 0.1% CH gluconate, 15% ethanol, and normal saline mixture i.p. for three weeks in order to induce SEP. CH + adalimumab group received 5 mg/kg adalimumab i.p. at the beginning of week 4 and week 6, while CH + resting group was followed-up for three weeks without applying any procedure after the onset of SEP. Rats in groups CH and control group were sacrificed on day 21, and rats in group CH + adalimumab and CH + resting were sacrificed on day 42. All groups were evaluated for peritoneal thickness, inflammation, vascularization, and fibrosis.
Results:
CH + adalimumab group showed a significant decrease in peritoneal thickness, fibrosis score, and vascular score compared with CH group and CH + resting group.
Conclusion:
Adalimumab can prevent SEP development.
